<DOC>
	<DOCNO>NCT02798328</DOCNO>
	<brief_summary>Observational trial evaluate effectiveness TEG6s DOAC cartridge detect classify presence DOAC drug subject .</brief_summary>
	<brief_title>Direct Oral Anticoagulant Assay Detection &amp; Classification Study TEG 6S System</brief_title>
	<detailed_description />
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>â‰¥ 18 year old DOAC administer minimum 7 day Genetic Bleeding disorder . Known subsequently discover inherited defect coagulation ( e.g . hemophilia Von Willebrand disease ) Not know last two DOAC dos administer prior blood draw DOAC first administer ( resumed temporary cessation ) less 7 day prior blood draw DOAC dosage outside manufacturer 's recommended range ( e.g . study subject renal impairment supratherapeutic dose ) Heparin LMWH administer within 7 day prior blood draw On medication know affect coagulation status list Bruising , wound scar area venipuncture List medication know affect coagulation status 1 . Vitamin K Antagonists [ VKAs ] Warfarin Phenprocoumon Acenocoumarol Tecarfarin [ ATI5923 ] Phenindione Anisindione Elinogrel Vorapaxar Atopaxar 2 . Heparin Heparins Unfractionated Heparin [ UFH ] LMWH Fondaparinux Idraparinux Danaparoid 3 . Vasopressin Analogues DDAVP 4 . Direct Thrombin [ IIa ] Inhibitors Hirudin Lepirudin Bivalirudin Argatroban 5 . Defibrinating Agents Ancrod</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>